Michalis A. Michael
November 2, 2026
A brand can lead patient conversation and still trail with the prescribers who decide.
How pharma teams track HCP sentiment online, what prescribers talk about, and how to read it alongside field and market research.
What healthcare professionals (HCPs) think of a treatment shapes whether it gets prescribed. Pharma teams usually learn this through field force feedback, market research, advisory boards and conversations with key opinion leaders. All of these are valuable, and all of them are periodic.
HCPs also talk about treatments online, every day. Tracking that conversation gives brand, medical and insights teams a continuous view of prescriber sentiment between research cycles.
HCP conversations happen in more places than most teams expect:
HCPs talk differently from patients. Their posts are more clinical and often more critical, which makes them especially useful for:
Patients usually post far more than HCPs. If you measure sentiment across all conversation, patient voices dominate and HCP views disappear. A brand can lead patient conversation and still trail with the prescribers who decide.

HCP language also needs its own models. A word that signals frustration from a patient can be a neutral clinical observation from a doctor. Sentiment has to be scored within each audience, not across all of them.
Classifying a post as coming from an HCP relies on several signals: professional credentials in a profile, clinical language, and the context of the conversation. AI models do the first pass, and analysts check samples to keep the classification accurate. No method is perfect, which is why accuracy targets should be agreed and measured.

Online HCP sentiment can't tell you how prescribers will react to a product that isn't on the market yet, because nobody is discussing it. For pre-launch questions, advisory boards and research are still the tools.
Posts from HCPs can also describe adverse events. Those need to be confirmed and escalated to your pharmacovigilance team through an agreed process, as explained in our guide to adverse events in social media listening.
listening247 analyses patients, HCPs and carers separately, with custom models trained only for your therapeutic areas. Accuracy is written into the contract: at least 80% F1 on sentiment and topics, 90% on brand relevance and over 90% for adverse events. Insight reports and recommendations arrive at the cadence you prefer, and every possible adverse event is confirmed by an analyst and escalated to your pharmacovigilance team on your timelines.
Read our full guide to social listening for pharma, or see how HCPs talk about your brand with a free brand snapshot, presented in a 15-minute meeting.
Some professional communities can be included when you give us access. Others remain closed, and a good provider is clear about what it can and can't see.
HCPs focus on evidence, efficacy, safety and access, and use clinical language. Their sentiment has to be measured separately so it isn't drowned out by the larger volume of patient posts.